Charles River's (CRL) RMS Growth Aids Amid FX Headwind

Charles River Laboratories' (CRL) Research Models and Services (RMS) business continues to benefit from the Charles River Accelerator and Development Labs (CRADL) initiative. Yet, the global business environment remains challenging, denting the company's growth. The stock carries a Zacks Rank #3 (Hold). Within RMS, the company, in November 2023, acquired a 41% additional stake in Noveprim, a NHP provider of Mauritius. This acquisition led to a 90% controlling interest in Noveprim, firmly supporting Charles ...